This $1,211,469 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a therapeutic intervention research project to reverse gastric precancer conducted by Vanderbilt University Medical Center (VUMC). The award, with a performance period from June 1, 2024 to May 31, 2028, will enable VUMC to leverage its clinical expertise and research capabilities to advance medical knowledge and improve patient care. As a leading recipient of federal grants, VUMC has extensive experience managing multi-year, multi-million dollar awards from agencies like the National Institutes of Health and the Department of Defense. This project grant represents a strategic investment in biomedical research that aims to develop innovative therapeutic approaches to address critical health challenges relevant to military personnel and the broader public.